Quick Dispatch:
Your soul trial oral semaglutide Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your soul trial oral semaglutide Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design ships.
Need Help?
Questions about soul trial oral semaglutide Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for soul trial oral semaglutide Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design in your area.
Oral Semaglutide Show Promise as New Benchmark for Diabetes Care, Cardiovascular Protection
20.67
Please summarize the design, population, outcomes, and safety of the SOUL trial evaluating oral semaglutide 14 mg daily in adults aged 50 years or older with type 2 diabetes and established atherosclerotic
25.31
NEJM Editorial Fellow Harleen Marwah, MD, summarizes the SOUL trial. Read the full trial results at NEJM.org (link in bio). , , #ACC25 #Cardiology #ClinicalTrials #NEJM
27.72
SOUL: Oral Semaglutide Benefits Extend to Heart Failure
27.43
Oral Semaglutide Reduces Risk of MACE for Patients With Type 2 Diabetes
26.13
Oral Semaglutide Reduces Cardiovascular Risk in Type 2 Diabetes: Results from SOUL Trial
29.58
Tirzepatide for Weight Loss
25.65
